Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies, TEMPO Study

Inclusion Criteria

• Patients must have stage IV peritoneal surface dissemination of gastrointestinal cancer or stage 3B or 3C peritoneal surface dissemination of ovarian cancer that cannot be completely resected at time of abdominal exploration. Radiographically measurable disease is preferable, but for patients with previously documented gastrointestinal or ovarian cancer, for whom tumor markers (CEA or CA-125) have been useful markers of disease progression and/or response to treatment, a rising tumor marker (CEA or CA-125) could be substituted for radiographic imaging
• Subjects must have had at least one prior round of systemic therapy or have refused or be ineligible for standard systemic therapy for their disease type
• Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
• Absolute neutrophil count (ANC) >= 1,500/uL
• Platelets >= 100,000/uL
• Hemoglobin (Hgb) >= 8 g/dL
• Serum creatinine =< 1.5 x upper limit of normal (ULN), OR 24-hour creatinine clearance >= 60 mL/min for subject with creatinine levels > 1.5 x ULN
• Serum bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for a subject with total bilirubin level > 1.5 x ULN
• Aspartate aminotransferase (AST) =< 3 x ULN
• Alanine aminotransferase (ALT) =< 3 x ULN
• Alkaline phosphatase =< 3 x ULN
• Institutional normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/aPTT must be within therapeutic range of intended use of anticoagulants (and may need to be held per institutional standards for placement of the Bard peritoneal catheter)
• Patients must be recovered from both acute and late effects of any prior surgery, radiotherapy or other antineoplastic therapy
• Patients of reproductive potential (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) at the time of pregnancy test (women of childbearing potential only), during the course of the study and for 90 days after the last dose of study drug, even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of study and for 90 days after the last dose of study drug
• Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial

Exclusion Criteria

• Prior chemotherapy, radiotherapy, biological cancer therapy, targeted therapy, or major surgery within 28 days prior to enrollment or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment
• Patients who received radiotherapy to more than 25% of their bone marrow
• Currently receiving treatment with another investigational device or drug study, or < 30 days since ending treatment with another investigational device or drug study(s). Other investigational procedures while participating in this study are excluded
• Known active central nervous system (CNS) metastases. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids > 10 mg/day of prednisone or equivalent. The exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability
• Metastatic disease in a site other than the peritoneal surfaces
• History or evidence of active autoimmune disease that requires systemic treatment (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
• Evidence of clinically significant immunosuppression such as the following: * Primary immunodeficiency state such as severe combined immunodeficiency disease. * Concurrent opportunistic infection. * Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 7 days prior to enrollment
• History of allogenic organ or hematopoietic transplant
• Active herpes simplex virus (HSV) that requires intermittent or chronic systemic anti-herpetic therapy or prior complications of herpetic infection, e.g. herpetic keratitis or encephalitis
• Requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use
• Prior treatment with talimogene laherparepvec or any other oncolytic virus
• Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing
• Prior therapy with tumor vaccine
• Receipt of a live vaccine within 28 days prior to enrollment
• Known to have acute or chronic active hepatitis B or C infection (active, previously treated, or both)
• Known history of human immunodeficiency virus (HIV) infection
• Active infection or fever >= 101.3 degrees Fahrenheit (F) within 3 days of the first scheduled day of protocol treatment
• Peripheral neuropathy >= grade 2
• Bleeding disorders that would preclude intraperitoneal port placement
• Refractory ascites that requires palliative paracentesis more frequently than once a month. Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient’s ability to sign informed consent, cooperate and participate in the study or interferes with the interpretation of the results
• History of other malignancy within the past 5 years
• Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment or through 90 days after the last dose of talimogene laherparepvec
• Subjects of childbearing potential who are unwilling to use acceptable method(s) of effective contraception during study treatment and through 90 days after the last dose of talimogene laherparepvec
• Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 90 days after treatment with talimogene laherparepvec